We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.
- Authors
Orringer, E P; Casella, J F; Ataga, K I; Koshy, M; Adams-Graves, P; Luchtman-Jones, L; Wun, T; Watanabe, M; Shafer, F; Kutlar, A; Abboud, M; Steinberg, M; Adler, B; Swerdlow, P; Terregino, C; Saccente, S; Files, B; Ballas, S; Brown, R; Wojtowicz-Praga, S; Grindel, J M
- Abstract
Sickle cell disease (SCD) can cause severe painful episodes that are often thought to be caused by vaso-occlusion. The current therapy for these uncomplicated painful episodes includes hydration, oxygen, and analgesics. Purified poloxamer 188 may increase tissue oxygenation and thereby reduce inflammation, pain, and the overall duration of such painful episodes in patients with SCD.
- Publication
JAMA, 2001, Vol 286, Issue 17, p2099
- ISSN
0098-7484
- Publication type
Journal Article
- DOI
10.1001/jama.286.17.2099